Tailored medication communication is key to preventing patient harm across transitions of care Older patients are likely to have complex medication regimens, which need to be carefully managed as they move across and within diverse settings, including primary care, acute care, geriatric rehabilitation, and aged care facilities. These movements often involve different health professionals, such as general practitioners and medical specialists. Problems with medication communication across transitions of care are the key reasons for increased risk of medication-related problems and hospital readmissions.1-3 Discussions with older patients and families are often not prioritised across transitions of care; instead, fleeting conversations take place at irregular time points and for short periods just before or after transfers.4 These conversations are rarely organised in a goal-directed way where medication communication is conveyed accurately, clearly and comprehensively. The impact of fleeting conversations is that even if medication information is conveyed, patients and families may not be involved in key decisions about newly prescribed, ceased or changed medications, or may not voice their concerns and preferences about the medication regimen.5 There is lack of recognition that “the one person who remains constant is the patient, who has the most to lose in a disconnected health system”.6 Communication for shared medication decision making across transitions of care is largely disorganised and serendipitous.7, 8 Shared medication decision making involves health professionals, older patients and families communicating together to define the medication problem, outlining available options, checking understanding, eliciting patient and family values, supporting patient and family deliberation, and reaching mutual agreement.9 Currently, older patients and families have to display extensive fortitude and perseverance to express their view.7, 8 For many health professionals, medication communication comprises information-giving and information-receiving activities,10 where they do not enquire about older patients’ experiences, beliefs and attitudes about medication .7, 8 Eliciting patient and family priorities and preferences in medication decision making is often perceived as challenging, impractical and time consuming.7, 8 Nevertheless, if medication communication is to facilitate shared decision making, a shift is needed from information-giving and information-receiving consultations to interactive, tailored and deliberate conversations along the continuum of care.11 Although not all patients and families may want to be involved, creating opportunities will help to reduce fear and anxiety and to support those unwilling or unable to participate. Many factors contribute to health professionals’ ability to facilitate engagement with older patients and families.5 Older patients with complicated medication regimens, those with mental health problems, those from lower socio-economic backgrounds or low literacy, and Aboriginal and Torres Strait Islander and migrant populations are particularly at risk.6 Older patients may wish to evade responsibility for fear of making inappropriate decisions, or may believe they lack the ability to participate because of language, cultural, cognitive, and disease-related barriers.8 Related to medication decision making is the ethical and legal requirement to obtain informed consent before prescribing medication.12 If the older patient lacks decision-making capacity, their substitute decision maker such as a family member should make the decision. They have the right to decline prescribed medication, even if this view is contrary to medical recommendations. Similarly, they may change their mind and withdraw consent about prescribed medication at any time.12 Fostering engagement among older patients and families and creating opportunities for decision making about medications are crucial for improved safety and quality across transitions of care. Challenging fleeting conversations is key to reducing the risk of medication-related problems and patient harm. We acknowledge funding support relating to this paper, from the Australian Research Council through the Discovery Project Grant scheme (DP170100308). The funding source had no role in the planning, writing or publication of the work. Open access publishing facilitated by Deakin University, as part of the Wiley - Deakin University agreement via the Council of Australian University Librarians. No relevant disclosures. Not commissioned; externally peer reviewed.
Read full abstract
Nov 8, 2024
Joscelin Givens + 1
Just Published
Open Access